




PATENT  
ATTORNEY DOCKET NO. 50291/016003

Certificate of Mailing: Date of Deposit: November 8, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Jeremy Waterman

Printed name of person mailing correspondence

  
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Christer Nordstedt et al. Art Unit: 1631  
Serial No.: 10/721,774 Examiner: Michael L. Borin  
Filed: November 26, 2003 Customer No.: 21559  
Title: Peptide Binding the KLVFF-Sequence of Amyloid-Beta

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the merits.

Applicants note that an Information Disclosure Statement and a Form PTO-1449 were filed in this case on November 26, 2003, and that they have not yet received an initialed copy of the Form PTO-1449. Applicants thus request an initialed copy of the Form PTO-1449.


If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: November 8, 2005

Susan M. Michaud  
Susan M. Michaud  
Reg. No. 42,885

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045



Sheet 1 of 1

SUB-TRADE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50291/016003
	Serial No.	10/721,774
	Applicant	Christer Nordstedt et al
	Filing Date	November 26, 2003
	Group	1631
	IDS Filed	November 8, 2005

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date/Date of Issue	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	5,593,846	1-14-1997	Schenk et al.			
	5,753,624	5-19-1998	McMichael et al.			
	5,780,587	7-14-1998	Potter			
	5,851,996	12-22-1998	Kline			
	5,854,204	12-29-1998	Findeis et al.			
	5,985,242	11-16-1999	Findeis et al.			
	6,114,133	9-5-2000	Seubert et al.			
	6,303,567	10-16-2001	Findeis et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 96/39834	12-19-1996	WIPO			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Camilleri et al., "β-Cyclodextrin Interacts with the Alzheimer Amyloid β-A4 Peptide," FEBS Letters 341:256-258, 1994.					
	Fraser et al., "Effects of Sulfate Ions on Alzheimer β/A4 Peptide Assemblies: Implications for Amyloid Fibril-Proteoglycan Interactions," J. Neurochem. 59:1531-1540, 1992.					
	Lorenzo et al., "β-Amyloid Neurotoxicity Requires Fibril Formation and is Inhibited by Congo Red," Proc. Natl. Acad. Sci. USA 91:12243-12247, 1994.					
	Wood et al., "Prolines and Amyloidogenicity in Fragments of the Alzheimer's Peptide β/A4," Biochem. 34:724-730, 1995.					

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	